CPX-351与维奈克拉联合阿扎胞苷治疗急性髓系白血病的真实世界疗效比较
本研究利用全国电子健康记录数据库及宾夕法尼亚大学电子健康记录,回顾性观察比较CPX-351(n=217)与维奈克拉联合阿扎胞苷(ven/aza,n=439)初治急性髓系白血病(AML)患者的总生存期及安全性。中位总生存期整体为12个月,两组无统计学显著差异(CPX-351 13个月 vs ven/aza 11个月;HR 0.88;95%CI 0.71-1.08;P=0.22)。CPX-351组记录感染及发热性中性粒细胞减少发生率更高,住院时间更长。
要点
- CPX-351与ven/aza初治AML患者的中位OS无统计学显著差异(HR 0.88;95%CI 0.71-1.08;P=0.22)。
- ven/aza组患者年龄更大、更多在社区接受治疗、更多为新发AML诊断。
- CPX-351组记录感染和发热性中性粒细胞减少发生率更高,住院时间超过两倍。
核心结论
- 在这项大型多中心真实世界数据集中,CPX-351与ven/aza两组总生存期无统计学显著差异。
- 作者认为需要开展前瞻性随机研究,关注副作用、生活质量及对移植结局的影响。
研究设计与样本
- 研究为回顾性观察性研究,使用全国电子健康记录衍生的去标识数据库及宾夕法尼亚大学电子健康记录。
主要发现
- 全部患者中位总生存期为12个月,两组无差异(CPX-351 13个月 vs ven/aza 11个月;HR 0.88;95%CI 0.71-1.08;P=0.22)。
- 多项敏感性分析中总生存期结果相似。
- 60天早期死亡率两组相似(CPX-351 10% vs ven/aza 13%)。
- CPX-351组记录感染发生率及发热性中性粒细胞减少发生率均高于ven/aza组。
- CPX-351组住院时间(包括下一周期治疗前的任何入院)超过ven/aza组的两倍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CPX-351 and venetoclax and azacitidine (ven/aza) are both indicated as initial therapy for acute myeloid leukemia (AML) in older adults. In the absence of prospective randomized comparisons of these regimens, we used retrospective observational data to evaluate various outcomes for patients with newly diagnosed AML receiving either CPX-351 (n = 217) or ven/aza (n = 439). This study used both a nationwide electronic health record (EHR)-derived de-identified database and the University of Pennsylvania EHR. Our study includes 217 patients who received CPX-351 and 439 who received ven/aza. Paitents receiving ven/aza were older, more likely to be treated in the community, and more likely to have a diagnosis of de novo acute myeloid leukemia. Other baseline covariates were not statistically significantly different between the groups. Median overall survival (OS) for all patients was 12 months and did not differ based on therapy (13 months for CPX-351 vs 11 months for ven/aza; hazard ratio, 0.88; 95% confidence interval, 0.71-1.08; P = .22). OS was similar across multiple sensitivity analyses. Regarding safety outcomes, early mortality was similar (10% vs 13% at 60 days). However, documented infections were higher with CPX-351 as were rates of febrile neutropenia. Hospital length of stay, including any admission before the next cycle of therapy, was more than twice as long for CPX-351. In this large multicenter real-world dataset, there was no statistically significant difference in OS. Prospective randomized studies with careful attention to side effects, quality of life, and impact on transplant outcomes are needed in these populations.
引用
- Matthews AH, Perl AE, Luger SM, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022. PMID: 35507945. doi:10.1182/bloodadvances.2022007265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。